Format

Send to

Choose Destination
Mater Sci Eng C Mater Biol Appl. 2016 Dec 1;69:577-83. doi: 10.1016/j.msec.2016.07.009. Epub 2016 Jul 6.

Methotrexate intercalated calcium carbonate nanostructures: Synthesis, phase transformation and bioassay study.

Author information

1
Jiangsu Key Laboratory of Biofunctional Material, College of Chemistry and Material Science, Nanjing Normal University, Nanjing 210023, China.
2
Jiangsu Key Laboratory of Biofunctional Material, College of Chemistry and Material Science, Nanjing Normal University, Nanjing 210023, China; Jiangsu Provincial Key Laboratory of Palygorskite Science and Applied Technology, Huaiyin Institute of Technology, Huaian 223003, PR China. Electronic address: lishuping@njnu.edu.cn.
3
Jiangsu Key Laboratory of Biofunctional Material, College of Chemistry and Material Science, Nanjing Normal University, Nanjing 210023, China. Electronic address: lishuping@njnu.edu.cn.

Abstract

The formation and stabilization of amorphous calcium carbonate (ACC) is an active area of research owing to the presence of stable ACC in various biogenic minerals. In this paper, the synthesis of calcium carbonate (CaCO3) under the participation of methotrexate (MTX) via a facile gas diffusion route was reported. The results indicated that the addition of MTX can result in the phase transformation of CaCO3, and then two kinds of hybrids, i.e., MTX-vaterite and stable MTX-ACC came into being. Interestingly, the functional agent MTX served as both the target anticancer drug loaded and effective complexation agents to modify and control the morphology of final samples. The examination of MTX-ACC biodegradation process revealed that the collapse of MTX-ACC nanoparticles was due to the synergistic effect of drug release and the phase transformation. Finally, our study also proved that MTX-ACC exhibited the most excellent suppressing function on the viability of cancer cells, especially after long-time duration.

KEYWORDS:

Amorphous; Bioassay explore; Calcium carbonate; Drug loading; Methotrexate; Phase transformation

PMID:
27612750
DOI:
10.1016/j.msec.2016.07.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center